Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compnyโs lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
์ข
๋ชฉ ์ฝ๋ DYAI
ํ์ฌ ์ด๋ฆDyadic International Inc
์์ฅ์ผNov 05, 2004
CEOEmalfarb (Mark A)
์ง์ ์6
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃNov 05
์ฃผ์1044 North U.S. Highway One
๋์JUPITER
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ33477
์ ํ15617438333
์น์ฌ์ดํธhttps://dyadic.com/
์ข
๋ชฉ ์ฝ๋ DYAI
์์ฅ์ผNov 05, 2004
CEOEmalfarb (Mark A)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์